Therapeutic Vaccines Market By Disease Indication (Cancer, Infectious Diseases, Autoimmune Disorders, Neurological Conditions); By Technology (Dendritic Cell Vaccines, Tumor Cell Vaccines, DNA-based Vaccines, mRNA Vaccines, Viral Vector Vaccines, Protein/Peptide Vaccines); By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Therapeutic Vaccines Market will expand steadily between 2024 and 2030, with CAGR of 7.8% , valued at approximately USD 21.6 billion in 2024 and expected to reach USD 34.1 billion by 2030 , according to Strategic Market Research.

 

Therapeutic vaccines are not designed for prevention like traditional immunizations. Instead, they aim to treat existing diseases by activating the immune system against persistent infections, cancers, or chronic conditions. This subtle but powerful shift makes them strategically relevant in modern medicine.

 

Several macro forces are shaping this market:

• Cancer burden continues to climb globally, making oncology-focused vaccines a top priority. From cervical cancer (HPV-related) to melanoma, therapeutic vaccines are being tested as frontline and adjunct treatments.

• Chronic viral infections such as HIV, hepatitis B, and herpes remain unmet medical needs. Vaccines designed to suppress viral reservoirs rather than eliminate viruses outright are under intense clinical development.

• Regulatory momentum is building. Agencies in the U.S. and Europe are granting more expedited review pathways for novel immunotherapies, including therapeutic vaccines that show strong early-phase results.

• Technology convergence is redefining vaccine design. Platforms such as mRNA, dendritic cell vaccines, and viral vectors are pushing the field far beyond the protein-based vaccines of the past.

The strategic importance of therapeutic vaccines lies in their dual role: they blend preventive medicine’s scalability with oncology and infectious disease’s precision. Unlike monoclonal antibodies or small molecules, therapeutic vaccines promise durable immune memory, potentially lowering relapse rates and long-term costs.

 

The stakeholder map here is complex. Pharmaceutical giants are co-developing vaccine-oncology combinations with checkpoint inhibitors. Biotech startups are piloting mRNA-based therapeutic vaccines for rare cancers. Governments and public health agencies are investing heavily in therapeutic vaccines for HIV and TB, particularly in low- and middle-income countries. Meanwhile, investors see this as one of the few biopharma segments where platform technologies (like mRNA or DNA vaccines) can be monetized across multiple indications.

 

To be honest, therapeutic vaccines are at an inflection point. Ten years ago, they were dismissed as an experimental niche. Now, with proven efficacy in select cancers and unprecedented speed in vaccine development post-COVID, the field has real momentum. The next six years will determine whether they become mainstream therapies or remain specialized adjuncts.

 

Market Segmentation And Forecast Scope

The therapeutic vaccines market spans multiple diseases, technologies, and delivery formats — and its segmentation is evolving as the field matures. For this report, the market is segmented across four primary axes :

By Disease Indication

• Cancer: The most dominant segment, therapeutic vaccines in cancer are used for melanoma, cervical, lung, and prostate cancers. Many are deployed in combination with checkpoint inhibitors, with a growing emphasis on personalized neoantigen-based vaccines.

• Infectious Diseases: The fastest-growing segment. Renewed R&D in HIV, hepatitis B, herpes, and even tuberculosis is driving pipeline momentum. Vaccines in this segment aim to suppress viral reservoirs or induce functional cure — not just immune stimulation.

• Autoimmune Disorders: Still emerging, but gaining interest in multiple sclerosis, Type 1 diabetes, and inflammatory bowel disease. The goal is immune modulation rather than stimulation — a reversal of traditional vaccine logic.

• Neurological Conditions: A niche but promising area. Early efforts include vaccines targeting Alzheimer’s disease pathology and chronic neuroinflammation. Most programs remain preclinical but could reshape immunotherapy in CNS disorders.

In 2024, cancer accounts for 54% of total market revenue, but infectious diseases are set to grow faster through 2030 as therapeutic strategies move beyond oncology into chronic viral management.

 

By Technology Type

• mRNA Vaccines: The fastest-growing platform, catalyzed by COVID-19 validation. mRNA allows for rapid design, personalization, and multi-antigen payloads, especially in oncology and HIV.

• Viral Vector Vaccines: Mature and widely used in oncology and infectious diseases. These platforms offer longer antigen expression, but face scalability and vector immunity concerns.

• Dendritic Cell Vaccines: Known for their potent T-cell activation. Despite manufacturing complexity, they’re gaining traction in combination immunotherapies.

• DNA-based Vaccines: Still niche, but favored for chronic infection targets due to their stability and low-cost potential — often paired with electroporation delivery.

• Protein/Peptide Vaccines: Used in off-the-shelf models, especially for tumor-associated antigens (TAA). Scalability is high, but immunogenicity often requires strong adjuvants.

• Tumor Cell Vaccines: Personalized but logistically intensive. These vaccines use autologous tumor cells to create patient-specific immunization strategies, typically in early-phase cancer trials.

In 2024, mRNA and viral vector platforms lead in commercial readiness, but dendritic cell and peptide vaccines are becoming more modular — a shift that could unlock wider use by 2026.

 

By Route of Administration

• Intramuscular (IM): The most common route, favored for mRNA and viral vector vaccines due to familiarity and established injection protocols.

• Subcutaneous (SC): Gaining ground in autoimmune and infectious disease trials, where depot effects support sustained antigen presentation.

• Intradermal (ID): Emerging as a precision route for localized immune priming. Microneedle arrays and ID injection pens are being explored for high-potency, low-volume vaccines.

• Others (e.g., intranodal, oral): Still experimental, but attractive for their targeted lymph node delivery or ease of use in low-resource settings.

While IM remains dominant in 2024, SC and ID administration are projected to grow faster through 2030 as delivery technologies improve and patient comfort becomes a competitive differentiator.

 

By Region

• North America: The largest and most advanced market, led by U.S.-based trials in oncology and chronic viral infections. Expedited regulatory pathways and payer interest in immune-durable therapies support strong early adoption.

• Europe: Scientifically robust but more conservative in pricing and uptake. Countries like Germany, France, and the Netherlands are hubs for HPV-related and hepatitis B therapeutic vaccines, often backed by EU funding initiatives.

• Asia-Pacific: The fastest-growing region, powered by rising investment in cancer immunotherapy (China, Japan, South Korea) and a strong infectious disease pipeline in India and Southeast Asia. Local manufacturing capacity is also accelerating time-to-market.

• Latin America: In the early phases of adoption. Brazil and Mexico are building clinical trial infrastructure, with interest in therapeutic vaccines for cervical cancer and HIV. Pricing and access remain hurdles.

• Middle East & Africa (MEA): Emerging markets with a focus on public health applications. South Africa and Saudi Arabia are piloting therapeutic vaccines in HIV and TB programs, supported by NGOs and global funders.

In 2024, North America holds over 40% of global revenue, but Asia-Pacific is projected to outpace all regions in growth through 2030 — driven by disease burden, public-private partnerships, and local biotech innovation.

 

Scope Note:

While the segmentation appears technical, it has clear commercial implications. Investors are evaluating not just disease verticals but also platform scalability — an mRNA therapeutic vaccine for HPV-related cancer today could mean rapid entry into HBV or EBV vaccine markets tomorrow.

Also, the lines between therapeutic and preventive vaccines are starting to blur , particularly in chronic viral infections. Some candidates are positioned for both indications depending on patient history, a nuance that could reshape how companies structure their pipelines.

 

Market Trends And Innovation Landscape

Therapeutic vaccines used to be the long shot in the immunotherapy race. That’s no longer the case. Over the past 24 months, a combination of scientific validation, biotech innovation, and regulatory openness has pushed this market into a new phase of credibility. Here's what’s driving the shift:

mRNA Isn’t Just for COVID Anymore

The mRNA revolution that enabled rapid COVID vaccine development is now spilling into therapeutic applications. Biotechs and big pharma are testing mRNA platforms in oncology , HIV , and hepatitis B — with early-phase trials showing durable immune responses and manageable safety profiles.

One oncology trial using an mRNA-based personalized vaccine in melanoma patients recently showed a significant reduction in recurrence when paired with checkpoint inhibitors. That success is turning mRNA into the backbone of next-gen therapeutic vaccine design.

 

Personalized Vaccines are Gaining Clinical Ground

Precision medicine isn’t just for drugs anymore. Therapeutic vaccines are now being tailored to individual tumor neoantigens , viral mutations , or immune profiles . Startups are using next- gen sequencing and AI to rapidly identify and encode the most immunogenic targets per patient.

The downside? Cost and logistics. Personalized vaccines currently require custom manufacturing workflows, but developers are racing to standardize parts of the process using modular platforms and AI-driven epitope prediction.

 

Checkpoint Combinations Are Becoming Standard Practice

Monotherapy vaccines still struggle in late-stage cancers, but combination strategies are outperforming expectations . Dozens of trials are exploring how therapeutic vaccines can amplify the effect of PD-1/PD-L1 inhibitors , CTLA-4 antibodies , or oncolytic viruses .

Regulators seem open to the approach. FDA and EMA have both shown willingness to fast-track trials where vaccines boost existing standard-of-care regimens — not replace them.

 

Infectious Disease is the Comeback Story

After years of stagnation, therapeutic vaccines for HIV , herpes simplex virus , and hepatitis B are back in focus. New immunogen design, better delivery vectors, and long-term viral reservoir understanding are enabling new formulations that go beyond traditional suppression.

One major pharma is now trialing a combination of a therapeutic HIV vaccine with broadly neutralizing antibodies to drive viral remission without daily ART. That kind of ambition would’ve been unthinkable five years ago.

 

Smart Delivery Platforms Are Redefining the Landscape

Intramuscular injection isn’t the only option anymore. Developers are testing intradermal microneedle arrays , implantable delivery systems , and intranodal injections to more precisely target immune-rich areas.

These approaches aim to improve both T-cell activation and memory response longevity — two areas where past vaccines fell short.

 

AI Is Quietly Powering Vaccine Design

Behind the scenes, machine learning is transforming antigen prediction, immune response modeling, and even trial enrollment. Platforms that once took months to design vaccine constructs now do it in hours, thanks to predictive AI models trained on thousands of immunopeptidomes .

One biotech recently shaved its vaccine candidate selection process from 8 months to 3 weeks using a proprietary AI engine. The implications for speed-to-clinic are massive — especially in oncology and rare diseases.

 

Bottom line: this isn’t about repurposing flu vaccine infrastructure. Therapeutic vaccines require new platforms, smarter targeting, and deeper immune science. But the momentum is real. This space is no longer experimental — it's executional. And companies that figure out scale and standardization will unlock multi-billion-dollar treatment categories.

 

Competitive Intelligence And Benchmarking

This market isn’t crowded — but it’s fierce. The companies competing in the therapeutic vaccines space fall into two camps: legacy pharma firms leveraging platform breadth, and biotech disruptors betting everything on one or two indications. What separates winners here is execution: not just scientific novelty, but scalable delivery, strategic partnerships, and immune durability.

Moderna

Moderna isn’t just riding the mRNA wave — it’s steering it. The company is in advanced-stage trials for a personalized cancer vaccine (mRNA-4157) in combination with Keytruda . Early results in melanoma showed a significant drop in recurrence rates, validating mRNA’s use in oncology beyond prevention.

What makes Moderna stand out is speed. Its mRNA platform allows rapid iteration and customization, making it a top player in neoantigen -driven vaccine design . And with cash reserves from COVID-19 sales, it has more room to experiment than most biotechs ever dream of.

 

BioNTech

Often mentioned in tandem with Moderna , BioNTech is quietly building a broader therapeutic portfolio. The company is advancing therapeutic vaccine candidates for pancreatic , colorectal , and prostate cancers , using both mRNA and TCR platforms .

Unlike others, BioNTech is emphasizing off-the-shelf tumor-associated antigen (TAA) vaccines in parallel with personalized options — which could scale more easily. They’ve also expanded R&D capabilities in Germany and the U.S. for oncology-focused immunotherapies.

 

GSK

GlaxoSmithKline has taken a strategic stance in therapeutic vaccines with strong investments in infectious diseases . Its therapeutic candidate for chronic hepatitis B is one of the most closely watched in the industry. GSK has also doubled down on adjuvant development, partnering with biotech firms to enhance immune durability of vaccine candidates.

They’ve maintained a robust pipeline in HPV-related cancers , banking on their long-standing experience in prophylactic vaccines to inform therapeutic advances.

 

Inovio Pharmaceuticals

This mid-sized biotech is focused on DNA-based therapeutic vaccines , especially in HPV-related cancers and infectious diseases like HIV . Inovio’s platform uses electroporation delivery to improve cellular uptake — a strategy that sets it apart, though it hasn’t yet translated into blockbuster results.

Still, Inovio has secured multiple government and NGO partnerships, particularly for low- and middle-income markets , which could serve as a foothold for larger expansion.

 

ISA Pharmaceuticals

A niche player, ISA is betting on synthetic long peptide (SLP) vaccines. Their lead candidate for HPV-induced head and neck cancer has shown encouraging immunogenicity in early trials. ISA’s approach is highly targeted — and while it's not yet commercial, its ability to induce CD8+ responses has caught the attention of academic oncology centers.

 

Hookipa Pharma

Another rising biotech , Hookipa is pioneering replicating viral vector vaccines for both cancer and chronic infections. Its clinical-stage candidates for head and neck cancer and cytomegalovirus use an engineered arenavirus platform that offers both systemic and mucosal immunity. That’s rare — and strategically valuable in sexually transmitted or respiratory infections.

 

Competitive Dynamics at a Glance:

• Moderna and BioNTech lead in platform scalability and oncology partnerships.

• GSK holds strength in infectious disease strategy and adjuvant science.

• Inovio and ISA operate in technology niches with early traction.

• Hookipa brings novel vector science into the therapeutic conversation.

That said, most players still face the same hurdles: complex manufacturing, expensive personalization, and long regulatory timelines. Unlike prophylactic vaccines, therapeutic ones demand repeated dosing, immune modulation, and disease-specific endpoints — which adds clinical risk.

 

To be honest, it’s a high-stakes space. But it's also where some of the most exciting immune science is playing out in real time. Success here won’t just shift treatment guidelines — it could redefine entire therapeutic categories.

 

Regional Landscape And Adoption Outlook

The therapeutic vaccines market has a truly global footprint, but the pace of development, regulation, and adoption varies sharply by region. While North America and Europe remain the innovation anchors, Asia-Pacific is emerging as a high-potential growth zone — and Latin America and Africa are beginning to attract interest through global health partnerships.

North America

Still the epicenter of innovation, North America — especially the United States — accounts for the largest market share. This is driven by:

• Access to early-stage clinical trial infrastructure

• Strong collaboration between academic hospitals and biotech firms

• Expedited regulatory pathways like Breakthrough Therapy Designation and Fast Track

Cancer-focused therapeutic vaccines dominate here, particularly in melanoma, lung, and HPV-related cancers. Major players like Moderna , BioNTech , and Inovio run most of their early-phase and pivotal trials in U.S. institutions.

The presence of payers willing to reimburse high-cost immunotherapies also supports real-world adoption once candidates are approved.

That said, cost pressures and growing scrutiny over specialty drug pricing may affect long-term reimbursement policies — especially for personalized or combination-based vaccines.

 

Europe

Europe matches North America in scientific depth but tends to be more conservative with regulatory approvals. Agencies like the European Medicines Agency (EMA) have supported several therapeutic vaccine trials under conditional marketing or PRIME designations, but market uptake can be slower due to pricing negotiations and health system fragmentation.

Countries like Germany , Sweden , and the Netherlands are leading in therapeutic vaccine R&D, often in academic-industry consortia.

France’s cancer immunotherapy ecosystem , supported by institutions like Institut Gustave Roussy , has also become a hub for first-in-human vaccine trials.

Europe is also a strong base for therapeutic vaccines targeting rare infectious diseases, with EU Horizon funding supporting vaccine work in tuberculosis and chronic hepatitis B.

 

Asia-Pacific

This region is on the rise — fast. China , Japan , and South Korea are increasing both local vaccine development capacity and cross-border licensing deals .

China’s large cancer burden and heavy government investment in biotech innovation make it a key growth market. Chinese firms are starting to co-develop therapeutic vaccine platforms, particularly in HPV-related cervical cancer and hepatitis B — both of which are highly prevalent.

Japan has shown growing interest in personalized peptide vaccines , especially for gastric and prostate cancers. Meanwhile, South Korea is building mRNA vaccine manufacturing hubs that could pivot toward therapeutic applications.

In India , the focus is still mostly preventive, but some private hospitals and startups are beginning to e xplore therapeutic vaccine R&D for TB and liver cancer — driven by local disease burden.

 

Latin America and the Middle East & Africa (LAMEA)

Currently underpenetrated, but not inactive.

In Brazil and Mexico , public-private partnerships are funding early-stage cancer immunotherapy trials, including therapeutic vaccine candidates in cervical and head & neck cancers. Access remains limited, but interest is rising as bioscience hubs expand.

In the Middle East , countries like Saudi Arabia and the UAE are investing in cancer research ecosystems as part of national health strategy reforms. These regions could become clinical trial destinations in the coming decade.

Africa presents the biggest adoption challenge — both in terms of infrastructure and affordability. However, interest in therapeutic vaccines for HIV and TB is strong in South Africa, where NGO-backed clinical research centers already operate at scale.

Global health funders like CEPI and Gates Foundation are beginning to steer attention toward therapeutic vaccines for neglected infectious diseases, which could change adoption dynamics in low-income countries.

 

Regional Summary:

• North America leads in pipeline and trial density, especially for cancer.

• Europe remains strong in scientific innovation but faces slower market uptake.

• Asia-Pacific is moving from manufacturing to discovery — and fast.

• LAMEA is still emerging, with potential centered around infectious disease control and NGO-backed pilot programs.

The common thread? Regardless of geography, success in therapeutic vaccines isn’t just about access to technology. It’s about navigating regulation, educating providers, and aligning with payer priorities.

 

End-User Dynamics And Use Case

Therapeutic vaccines don’t follow the same playbook as traditional immunizations. Their adoption depends heavily on the complexity of the disease, the delivery method, and whether the care setting can support advanced immunotherapy protocols. In this market, oncology clinics , specialty hospitals , and academic research centers are the real power users.

Oncology and Immunotherapy Centers

These facilities are the primary end users of therapeutic cancer vaccines. Typically located within large academic medical centers or private cancer networks, they:

• Run phase I–III clinical trials

• Have multidisciplinary tumor boards to guide vaccine use in treatment regimens

• Are equipped to manage immune-related adverse events

• Regularly use checkpoint inhibitors , with which therapeutic vaccines are often co-administered

Many of these institutions now include therapeutic vaccines in combination protocols , especially for patients with high relapse risk or minimal residual disease.

One example: In advanced melanoma cases, several U.S.-based cancer centers are now using personalized neoantigen vaccines post-surgery in patients with BRAF-negative tumors — a group that historically had limited targeted options.

 

Infectious Disease Clinics and Viral Load Management Centers

For chronic infections like HIV , hepatitis B , or HSV , therapeutic vaccines are being piloted in specialty clinics that manage long-term antiviral therapy . These centers are:

• Monitoring viral suppression

• Testing for reservoir activity

• Exploring vaccine-antibody combo therapies to reduce or eliminate lifelong medication dependence

While uptake here is still in the trial stage, clinicians are actively preparing for commercial rollout in low-dose maintenance regimens .

 

Academic Hospitals and Translational Research Hubs

These are where most first-in-human studies happen. Academic centers serve dual roles:

• As R&D collaborators (partnering with biotech firms)

• As early adopters for translational application of therapeutic vaccines

Their input is critical in refining delivery methods (e.g., dendritic cell prep, intranodal injection), immune response monitoring, and optimal treatment timing.

 

Government and Military Health Systems

In regions with high disease burden, especially from HIV or tuberculosis , public health agencies are now testing therapeutic vaccines as part of population-level chronic disease strategies . This includes:

• National HIV remission programs in South Africa and Brazil

• Military health programs exploring vaccines for latent infections in personnel

These settings require cost-effective , easily administered platforms — a key reason mRNA and viral vector approaches are gaining attention here.

 

Use Case Highlight

A tertiary cancer center in South Korea launched a pilot program in 2024 for patients with HPV-related head and neck cancers. Standard treatment includes radiation and surgery, but recurrence rates were high. The center integrated a therapeutic peptide vaccine post-radiation for 40 patients, combined with PD-1 inhibitors.

• Outcome? Tumor progression slowed in over 60% of cases

• Key win: Patients reported fewer long-term side effects versus chemotherapy

• Operational result: Hospital saved 18% in immunotherapy drug costs through fewer combination cycles

The program is now expanding to gastric cancer patients and may be used as a platform for broader personalized vaccine strategies.

 

Bottom line: therapeutic vaccine adoption isn’t about broad distribution. It’s about precision rollout — where infrastructure, expertise, and immune monitoring intersect. The most successful end users will be those that treat vaccines not as a one-off product, but as a system: diagnostics + delivery + post-treatment immune tracking .

 

Recent Developments + Opportunities & Restraints

Recent Developments (2023–2025)

The past two years have been pivotal for the therapeutic vaccines market. Several breakthroughs in oncology and infectious disease have not only validated the science — they’ve pulled the market into commercial focus.

• Moderna and Merck reported positive Phase IIb results in 2024 for their mRNA-based melanoma vaccine (mRNA-4157) combined with Keytruda . The trial showed a 44% reduction in recurrence risk, triggering fast-track designation from the FDA.

• BioNTech initiated multiple global trials in 2023 for its off-the-shelf pancreatic cancer therapeutic vaccine , aiming to overcome the limitations of tumor heterogeneity in highly fatal cancers.

• GSK announced a major Phase II expansion in 2025 for its HBV therapeutic vaccine candidate , following encouraging immunogenicity data in chronic infection patients. The program is part of a broader alliance with the Coalition for Epidemic Preparedness Innovations (CEPI).

• Hookipa Pharma received IND clearance from the U.S. FDA in 2024 to trial its replicating viral vector vaccine in HPV-related head and neck cancers, a notable step for novel vector science in therapeutic settings.

• ISA Pharmaceuticals reported completion of Phase I for its synthetic long peptide HPV vaccine , with durable CD8+ T-cell activation and tolerability in immunocompromised patients.

 

Opportunities

• Personalized Cancer Vaccines at Scale:
  What used to be a lab-intensive, bespoke therapy is slowly becoming scalable. With faster sequencing, AI-driven antigen selection, and mRNA delivery platforms, the window is open for commercial-grade personalized vaccines — especially in melanoma, colorectal, and lung cancers.

• Chronic Viral Disease Reversal:
  Therapeutic vaccines targeting HIV , hepatitis B , and even herpes are generating renewed attention. Their potential to reduce — or even eliminate — the need for lifelong antiviral medication is drawing both funding and regulatory interest.

• mRNA and Vector Platform Expansion:
  As delivery technologies mature, mRNA and viral vector platforms can be repurposed across disease verticals . Companies that crack one indication can quickly enter others — multiplying pipeline value without overhauling the core tech.

 

Restraints

• High Cost and Limited Reimbursement Models:
  Unlike preventive vaccines, therapeutic ones often require multiple doses, cold-chain logistics, and co-administration with immune checkpoint drugs — all of which drive up costs. Most health systems have no reimbursement pathway yet for personalized vaccines.

• Complex Manufacturing and Regulatory Uncertainty:
  Personalized or cell-based vaccine platforms don’t scale easily. Regulatory frameworks, especially outside the U.S. and EU, remain underdeveloped. This creates bottlenecks in market entry, particularly in Asia and Latin America.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 21.6 Billion
Revenue Forecast in 2030	USD 34.1 Billion
Overall Growth Rate	CAGR of 7.8% (2024–2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024–2030)
Segmentation	By Disease Indication, By Technology, By Route of Administration, By Geography
By Disease Indication	Cancer, Infectious Diseases, Autoimmune Disorders, Neurological Conditions
By Technology	Dendritic Cell Vaccines, Tumor Cell Vaccines, DNA-based Vaccines, mRNA Vaccines, Viral Vector Vaccines, Protein/Peptide Vaccines
By Route of Administration	Intramuscular, Subcutaneous, Intradermal, Others
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Germany, France, China, Japan, South Korea, India, Brazil, UAE, South Africa
Market Drivers	- Advancements in mRNA and personalized vaccine platforms - Rising cancer incidence and unmet need in chronic viral infections - Regulatory support for combo therapies and novel immunotherapeutics
Customization Option	Available upon request